These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15226491)

  • 1. Optimizing Efficacy in CARTIs: introduction.
    Nicolau DP
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S7. PubMed ID: 15226491
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-duration therapy for respiratory tract infections.
    Goff DA
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting the challenge of antibiotic resistance: The PROTEKT US study.
    Stratton CW
    Postgrad Med; 2002 Sep; 112(3 Suppl):7-11. PubMed ID: 19667589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
    Sbarbaro JA
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.
    Pfaller MA; Jones RN
    Postgrad Med; 2001 Feb; 109(2 Suppl):10-21. PubMed ID: 19667553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating community-acquired bacterial respiratory tract infections: update on etiology, diagnosis, and antimicrobial therapy.
    Brunton S
    J Fam Pract; 2005 Apr; 54(4):357-64. PubMed ID: 15833229
    [No Abstract]   [Full Text] [Related]  

  • 8. Community-acquired bacterial respiratory tract infections.
    Brunton S; Carmichael B; Fitzgerald M; Liu H; Varon J; Weiland D
    J Fam Pract; 2005 Mar; 54(3):255-62. PubMed ID: 15755379
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective use of antibiotics in managed care.
    Giaquinta D
    Manag Care Interface; 2005 Dec; 18(12):35-6, 48. PubMed ID: 16405223
    [No Abstract]   [Full Text] [Related]  

  • 10. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Sollet JP
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: PROTEKT against respiratory tract infection.
    Stratton CW
    J Chemother; 2002 Jul; 14 Suppl 3():5-8. PubMed ID: 12418555
    [No Abstract]   [Full Text] [Related]  

  • 12. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ; Jenkins SG
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections.
    Benninger M; Segreti J
    J Fam Pract; 2008 Feb; 57(2 Suppl Managing):S5-11. PubMed ID: 18662527
    [No Abstract]   [Full Text] [Related]  

  • 14. [Respiratory infections, always a relevant subject].
    Letonturier P
    Presse Med; 2008 Mar; 37(3 Pt 1):438-9. PubMed ID: 18338439
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
    Nicolau DP
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S381-8. PubMed ID: 15603247
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management of community-acquired lower respiratory tract infection in the adult. Recommendations by the French Language Society of Pneumology with collaboration of the French Language Society of Infectious Pathology, from the recommendations of the European Respiratory Society].
    Huchon G; Chidiac C; Delaval P; Léophonte P; Mouton Y; Roche N; Trémolières F
    Rev Mal Respir; 1999 Apr; 16(2):224-33. PubMed ID: 10339770
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 19. Appropriate antibiotic therapy for community-acquired respiratory tract infections.
    Gerbino PP; Brixner D; Sbarbaro J; Nicolau D
    Manag Care Interface; 2005 Dec; 18(12):41-8. PubMed ID: 16405224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.